Sosei Heptares and Biohaven Enter Global Collaboration and License Agreement to Advance Novel Small-Molecule CGRP Antagonist Portfolio
The Pharma Data
NOVEMBER 30, 2020
Biohaven acquires exclusive global rights to a portfolio of novel, small-molecule CGRP antagonists. We are now committed to pursuing other CGRP-mediated diseases through advancing novel investigational agents such as HTL0022562 into human studies.” TOKYO and CAMBRIDGE, England , Dec. Vlad Coric , M.D.,
Let's personalize your content